Abstract
PUMA (p53 upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2 family member and a key mediator of apoptosis induced by a wide variety of stimuli. PUMA is particularly important in initiating radiation induced apoptosis and damage in the gastrointestinal and hematopoietic systems. Unlike most BH3-only proteins, PUMA neutralizes all five known antiapoptotic Bcl-2 members through high affinity interactions with its BH3 domain to initiate mitochondria-dependent cell death. Using structural data on the conserved interactions of PUMA with Bcl-2-like proteins, we developed a pharmacophore model that mimics these interactions. In silico screening of the ZINC 8.0 database with this pharmacophore model yielded 142 compounds that could potentially disrupt these interactions. Thirteen structurally diverse compounds with favorable in silico ADME/Toxicity profiles have been retrieved from this set. Extensive testing of these compounds using cell-based and cell-free systems identified lead compounds that confer considerable protection against PUMA-dependent and radiation-induced apoptosis, and inhibit the interaction between PUMA and Bcl-xL.
Keywords: Inhibition of PUMA-induced apoptosis, Bcl-2 protein family, BH3 domain, protein-protein interactions, pharmacophore modeling, druggability, virtual screening of libraries of small compounds, PUMA Inhibitors, p53 upregulated modulator of apoptosis, Bcl-2 homology, hematopoietic systems, programmed cell death, neurodegenerative diseases, autoimmune disorders, radiotherapy, DNA damage, caspases, mitochondrial apoptotic pathway, cytochrome c, mitochondrial dysfunction, ZINC 8.0 database, ADME/Tox, molecular dynamics, colon cancer cells, adenovirus, DLD1 cells, Adriamycin, cyclin-dependent kinase, p21 KO cells, immunoprecipitation, inflammatory cytokines, reactive oxygen species, chemotherapy, anticancer therapies, CYP2D6 inhibition, Cell Culture, Molecular Probes, Western Blotting
Current Topics in Medicinal Chemistry
Title: Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death
Volume: 11 Issue: 3
Author(s): Gabriela Mustata, Mei Li, Nicki Zevola, Ahmet Bakan, Lin Zhang, Michael Epperly, Joel S. Greenberger, Jian Yu and Ivet Bahar
Affiliation:
Keywords: Inhibition of PUMA-induced apoptosis, Bcl-2 protein family, BH3 domain, protein-protein interactions, pharmacophore modeling, druggability, virtual screening of libraries of small compounds, PUMA Inhibitors, p53 upregulated modulator of apoptosis, Bcl-2 homology, hematopoietic systems, programmed cell death, neurodegenerative diseases, autoimmune disorders, radiotherapy, DNA damage, caspases, mitochondrial apoptotic pathway, cytochrome c, mitochondrial dysfunction, ZINC 8.0 database, ADME/Tox, molecular dynamics, colon cancer cells, adenovirus, DLD1 cells, Adriamycin, cyclin-dependent kinase, p21 KO cells, immunoprecipitation, inflammatory cytokines, reactive oxygen species, chemotherapy, anticancer therapies, CYP2D6 inhibition, Cell Culture, Molecular Probes, Western Blotting
Abstract: PUMA (p53 upregulated modulator of apoptosis) is a Bcl-2 homology 3 (BH3)-only Bcl-2 family member and a key mediator of apoptosis induced by a wide variety of stimuli. PUMA is particularly important in initiating radiation induced apoptosis and damage in the gastrointestinal and hematopoietic systems. Unlike most BH3-only proteins, PUMA neutralizes all five known antiapoptotic Bcl-2 members through high affinity interactions with its BH3 domain to initiate mitochondria-dependent cell death. Using structural data on the conserved interactions of PUMA with Bcl-2-like proteins, we developed a pharmacophore model that mimics these interactions. In silico screening of the ZINC 8.0 database with this pharmacophore model yielded 142 compounds that could potentially disrupt these interactions. Thirteen structurally diverse compounds with favorable in silico ADME/Toxicity profiles have been retrieved from this set. Extensive testing of these compounds using cell-based and cell-free systems identified lead compounds that confer considerable protection against PUMA-dependent and radiation-induced apoptosis, and inhibit the interaction between PUMA and Bcl-xL.
Export Options
About this article
Cite this article as:
Mustata Gabriela, Li Mei, Zevola Nicki, Bakan Ahmet, Zhang Lin, Epperly Michael, S. Greenberger Joel, Yu Jian and Bahar Ivet, Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death, Current Topics in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/156802611794072641
DOI https://dx.doi.org/10.2174/156802611794072641 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design HIV1-Human Protein-Protein Interaction Prediction (HHPPIP) Methodology: An FP-Growth Based Association Rule Mining Approach
Current Bioinformatics Current Targets for Anticancer Drug Discovery
Current Drug Targets Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Pulmonary Squamous Papilloma Complicating Recurrent Tracheal Papillomatosis
Current Respiratory Medicine Reviews Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives
Medicinal Chemistry Transcervical Oropharyngectomy: A Clinically Focused Review
Current Cancer Therapy Reviews The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Celecoxib in Cancer Therapy and Prevention – Review
Current Drug Targets Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Potent Inhibitors Against Bcl-xL Anti-apoptotic Protein Using Docking Studies
Protein & Peptide Letters Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents